P64 Real-world durability of effectiveness through 24 months of anti-interleukin-17A biologics and other approved biologics in treating patients with moderate-to-severe psoriasis in the Psoriasis Study of Health Outcomes
Year: 2024
Type: conference-abstract
Abstract: Introduction Patients with psoriasis (PsO) report that a quick and enduring response are key treatment goals. As such, more studies are needed to evaluate the treatment response of different biologics over long observation periods. To address this research gap, this analysis uses three different outcomes to evaluate the durability of treatment effectiveness of different biologics for patients with moderate-to-severe PsO from Week 12 through 2 years in a real-world setting. Methods The Psoriasis Study of Health Outcomes (PSoHO) is an ongoing, 3-year, international, prospective, non-interventional cohort study comparing the effectiveness of the anti-interleukin (IL)-17A cohort of ixekizumab (IXE) and secukinumab (SEC) to other approved biologics in patients with moderate-to-severe PsO initiating or switching to a newly approved biologic. The other biologics cohort includes adalimumab (ADA), brodalumab (BROD), certolizumab, etanercept, guselkumab (GUS), infliximab, risankizumab (RIS), tildrakizumab (TILD) and ustekinumab (UST). The first durability of effectiveness outcome was defined as the proportion of patients who achieved the primary endpoint of PASI90 and/or an sPGA score of 0 or 1 at Week 12, and who maintained a PASI75 score and/or an improvement of two points or more in sPGA from baseline at Months (M)6, M12 and M24. Two further analyses evaluated the proportion of patients who achieved PASI100 or PASI90 at Week 12 and maintained this result at M6, M12 and M24. Results Of the 1981 patients, 39.0% of patients were in the anti-IL-17A cohort and 61.0% received other biologics at baseline. A significantly higher proportion of patients in the anti-IL-17A cohort achieved each of the three outcomes measuring durability of effectiveness (P ≤ 0.001). For the individual treatments, 47.9% of IXE-treated patients, 46.3% of RIS-treated patients and 41.9% of SEC-treated patients achieved the first durability of effectiveness outcome. Over 14% of patients treated with BROD, RIS or IXE achieved a PASI100 response at Week 12 and maintained complete skin clearance through Month 24. Similarly, over 30% of patients treated with these biologics achieved the PASI90 durability response. As a non-interventional study, the number of patients varied across treatment groups and the small sample size of some biologics led to broader confidence intervals. Conclusion Evaluating PSoHO data at Week 12 and Months 6, 12, and 24, this analysis showed that the durability of treatment effectiveness in patients with moderate-to-severe PsO was significantly higher with anti-IL-17A biologics than other biologics in a real-world setting. Overall, this study highlights the importance of considering the durability of responses to treatments for patients with moderate-to-severe PsO.
Source: British Journal of Dermatology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4405229809